Citius Pharmaceuticals Operating Income

Citius Pharmaceuticals (CTXR) currently reports a operating income of $-57M as of March 2026. That compares with $-32M in the prior-year period — down 80.7% year over year. Use the charts on this page to explore Citius Pharmaceuticals's operating income history and peer comparisons.

Citius Pharmaceuticals's operating income decreased from $-32M to $-57M — a 80.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Citius Pharmaceuticals reported $-57M in operating income as of March 2026. That compares with $-32M in the prior-year period — down 80.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-57M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Citius Pharmaceuticals, and consider following CTXR for alerts when major investors trade the stock.

Citius Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-57M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTXR with unrelated industries.